Rechercher des projets européens

17 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Development of a Next-Generation, Dual-Target Rabies/Flavivirus Infectious DNA (iDNA) Vaccine (RABYD-VAX)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

Rabies is the deadliest disease on earth (99.9% fatality rate). Annually, ~58.000 people die from rabies, more than half of them are children. Many remain unvaccinated because of the high costs and the need for a cold-chain. Likewise, despite the existence of an excellent yellow fever (YF) vaccine, yearly ~30.000 people die of YF. The 80-year old low-tech production process does not allow to produ ...
Voir le projet

 5

 TERMINÉ 

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Voir le projet

 43

 TERMINÉ 

Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet

 26

 TERMINÉ 

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet

 49

 TERMINÉ 

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure (EDUFLUVAC)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,

"As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC ai ...
Voir le projet

 9

 TERMINÉ 

Use of PRIMate MOdels to support translational MEDicine and advance disease modifying therapies for unmet medical needs (PRIMOMED)

Date du début: 1 janv. 2014, Date de fin: 30 sept. 2015,

The focus of Primomed is the translational medicinal approach of the SMEs, i.e. developing disease modifying therapeutics for high unmet medical needs in chronic inflammatory and degenerative disorders. The Primomed project utilizes well characterized non-human primate models so that the SMEs can capitalize on subsequent clinical successes of their therapeutic lead compounds. The main objectives o ...
Voir le projet

 7

 TERMINÉ 

European Primate Network: Advancing 3Rs and International Standards in Biological and Biomedical Research (EUPRIM-NET II)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2015,

Biomedical research depends on the availability of living non-human primates and biological material with primate origin. The need for animal research using non-human primates is therefore recognised by all governments that support internationally competitive biomedical research aimed at addressing the world’s most pressing medical challenges. While essential for biomedical research owing to their ...
Voir le projet

 13

 TERMINÉ 

Towards the establishment of a permanent European Virtual Institute dedicated to Malaria Research (EVIMalaR) (EVIMalaR)

Date du début: 1 oct. 2009, Date de fin: 31 mars 2015,

This is a proposal from 55 partners from 36 institutes to form a NoE that will seek to integrate European malaria research that is directed towards a better understanding of the basic biology of the parasite, its vector and of the biology of the interactions between the parasite and both its mammalian host and vectors. All the member institutes and researchers have demonstrated both their excellen ...
Voir le projet

 40

 TERMINÉ 

Tolerance Restoration In Autoimmune Diseases by selective manipulation of the CD28 costimulatory pathway (TRIAD)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,

"The TRIAD, Tolerance Restoration In Autoimmune Disease, consortium provides an innovative strategy to autoimmune diseases (AID) therapy, based on antibody approach with a well established mechanism of action. The main objective is the evaluation of a selective antagonist of CD28 to prevent, treat and/or cure some AIDs in preclinical models including rheumatoid arthritis, multiple sclerosis, type ...
Voir le projet

 8

 TERMINÉ 

Identifying correlates of protection to accelerate vaccine trials: systems evaluation of two models of experimentally-induced immunity to malaria (SysMalVac)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2014,

Vaccine development is an empirical process (trial and error) and involves a long, expensive clinical development pipeline to license an efficacious vaccine candidate. Better tools for vaccine evaluation are needed to adapt to a rising number of candidate vaccines entering clinical trials for many diseases. Surrogate biomarkers of immunity offer the possibility of expediting the clinical developme ...
Voir le projet

 8

 TERMINÉ 

West Nile Integrated Shield Project: Epidemiology, Diagnosis and Prevention of West Nile Virus in Europe (WINGS)

Date du début: 1 févr. 2011, Date de fin: 28 févr. 2014,

The world is facing a variety of viral infections of high pathogenic potential. These are either novel or formerly only endemic in specific areas of the world. It is intrinsic to such emerging diseases that actions to prevent and fight them must be taken while the number of infections is still relatively low and geographically restricted. Therefore, research efforts are required well before large ...
Voir le projet

 10

 TERMINÉ 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet

 39

 TERMINÉ 

European Network of Vaccine Development and Research (TRANSVAC)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,

"The TRANSVAC infrastructure will accelerate the pharmaceutical and clinical development of promising vaccine candidates by bringing the gap between academic research and clinical trials through carefully managing the advancement of promising vaccine candidates from preclinical animal models to early proof-of-principle studies in humans. Although expertise already exists within Europe spanning dif ...
Voir le projet

 18

 TERMINÉ 

Signalling in life cycle stages of malaria parasites (MALSIG)

Date du début: 1 févr. 2009, Date de fin: 31 juil. 2012,

Malaria is a major public health problem in the developing world and is endemic in many regions of India. The development of novel strategies for malaria control requires a better understanding of the biology of malaria parasites. Our project aims at bringing a significant contribution to this field, through dissecting the signalling pathways that regulate essential processes in the life cycle o ...
Voir le projet

 18

 TERMINÉ 

Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation (OPTIMALVAC)

Date du début: 1 avr. 2009, Date de fin: 31 mars 2012,

"A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidem ...
Voir le projet

 14

 TERMINÉ 

"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges." (INYVAX)

Date du début: 1 févr. 2009, Date de fin: 31 janv. 2012,

"A number of new vaccines are being developed against Poverty-Related infectious diseases of major public health importance at a global level. The development of all those vaccines is facing the same kind of challenges and gaps, which still prevent 1) the establishment of readily accessible formulation and scale-up process development capacity for neglected diseases vaccines. 2) the establishment ...
Voir le projet

 10

 TERMINÉ 

Platform for the Harmonization of Vaccine Adjuvant Testing (PHARVAT)

Date du début: 1 nov. 2009, Date de fin: 31 oct. 2011,

"Adjuvants are critical to the quality and magnitude of immune responses generated by PRD vaccines. However, vaccine development is hampered by lack of access to appropriate adjuvants. This is partly because adjuvants are developed in many organizations, with individual models and protocols that have been established independently. The resulting data on adjuvants are only rarely directly comparabl ...
Voir le projet

 4